380 related articles for article (PubMed ID: 23229016)
21. Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients.
Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
Acta Haematol; 2012; 127(4):221-7. PubMed ID: 22473087
[TBL] [Abstract][Full Text] [Related]
22. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
Singh O; Chan JY; Lin K; Heng CC; Chowbay B
PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
[TBL] [Abstract][Full Text] [Related]
23. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
[TBL] [Abstract][Full Text] [Related]
24. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
25. Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Inokuchi K; Yamaguchi H; Tamai H; Dan K
J Clin Exp Hematop; 2012; 52(2):145-7. PubMed ID: 23037633
[No Abstract] [Full Text] [Related]
26. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
Ali MA; Elsalakawy WA
Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
[TBL] [Abstract][Full Text] [Related]
27. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
28. [Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia].
Chen WW; Meng FY; Zhong JS; Yin CX; Wang ZX
Zhonghua Yi Xue Za Zhi; 2012 May; 92(20):1405-8. PubMed ID: 22883199
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.
San José-Enériz E; Román-Gómez J; Jiménez-Velasco A; Garate L; Martin V; Cordeu L; Vilas-Zornoza A; Rodríguez-Otero P; Calasanz MJ; Prósper F; Agirre X
Mol Cancer; 2009 Sep; 8():69. PubMed ID: 19723306
[TBL] [Abstract][Full Text] [Related]
31. Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
Pinto CA; DE Sousa Portilho AJ; Barbosa MC; DE Moraes MEA; DE Lemos JAR; Burbano RMR; Moreira-Nunes CA
In Vivo; 2021; 35(5):2661-2667. PubMed ID: 34410954
[TBL] [Abstract][Full Text] [Related]
32. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
Kosztyu P; Bukvova R; Dolezel P; Mlejnek P
Chem Biol Interact; 2014 Aug; 219():203-10. PubMed ID: 24954033
[TBL] [Abstract][Full Text] [Related]
33. Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy.
Ferreira AF; de Oliveira GLV; Tognon R; Collassanti MDS; Zanichelli MA; Hamerschlak N; de Souza AM; Covas DT; Kashima S; de Castro FA
Acta Haematol; 2015; 133(4):354-364. PubMed ID: 25721555
[TBL] [Abstract][Full Text] [Related]
34. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy.
Sayed D; Badrawy H; Gaber N; Khalaf MR
Leuk Res; 2014 Feb; 38(2):243-50. PubMed ID: 24374144
[TBL] [Abstract][Full Text] [Related]
35. [Role of Lyn kinase in imatinib-resistant chronic myelogenous leukemia].
Liu J; Zhao XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1352-5. PubMed ID: 23257431
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
[TBL] [Abstract][Full Text] [Related]
37. ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
Corrêa S; Binato R; Du Rocher B; Ferreira G; Cappelletti P; Soares-Lima S; Pinto LF; Mencalha A; Abdelhay E
Epigenetics; 2014 Aug; 9(8):1172-83. PubMed ID: 25089713
[TBL] [Abstract][Full Text] [Related]
38. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
39. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Balabanov S; Gontarewicz A; Keller G; Raddrizzani L; Braig M; Bosotti R; Moll J; Jost E; Barett C; Rohe I; Bokemeyer C; Holyoake TL; Brümmendorf TH
PLoS One; 2011 Apr; 6(4):e19164. PubMed ID: 21541334
[TBL] [Abstract][Full Text] [Related]
40. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
Marin D; Bazeos A; Mahon FX; Eliasson L; Milojkovic D; Bua M; Apperley JF; Szydlo R; Desai R; Kozlowski K; Paliompeis C; Latham V; Foroni L; Molimard M; Reid A; Rezvani K; de Lavallade H; Guallar C; Goldman J; Khorashad JS
J Clin Oncol; 2010 May; 28(14):2381-8. PubMed ID: 20385986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
